Clinical trials: Treatment-refractory Schizophrenia
Refractory Schizophrenia
Occupational Therapy in the Rehabilitation of Executive Functions in Patients With Schizophrenia
Primary Objective: Efficacy of Occupational Therapy (OT) based Occupational Goal Intervention (OGI) in improving executive functions in patients with refractory schizophrenia as measured by the BADS.
- Trial name
- OTSchizo (NCT01879956)
- Testing
- Craft Activities, OGI Method
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo
Treatment Resistant Schizophrenia Based on the DTMS
Exploration of the Deep Transcranial Magnetic Stimulation for Treatment Resistant Schizophrenia
Negative symptoms and cognitive dysfunction are of importance for the prognosis of the patients of schizophrenia. Based on the hypothesis that deep transcranial magnetic stimulation(dTMS) on prefrontal cortex #PFC# could…
- Trial name
- NCT05167942
- Testing
- deep transcranial magnetic stimulation with H1 coil, High frequency deep transcranial magnetic stimulation with H1 coil, iTBS deep transcranial magnetic stimulation with H1 coil
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia
Famotidine in Schizophrenia
Objective of the trial is to study if famotidine add-on treatment is more effective than placebo add-on in reducing symptoms of schizophrenia among patients receiving insufficient response to ongoing antipsychotic treatment.
- Trial name
- NCT01946295
- Testing
- Famotidine
- Where
- 6 sites in Finland, Sweden
- Volunteers
- 140 people
- Sponsor
- Jesper Ekelund
Auditory Hallucination, Verbal, Treatment-resistant Schizophrenia
Avatar Therapy in Comparison to Cognitive Behavioral Therapy for Treatment-resistant Schizophrenia
Schizophrenia is associated with long-lasting health, social and financial burden for patients, families, caregivers and society. Unfortunately, 25-30% of schizophrenia patients respond poorly to antipsychotic medication.
- Trial name
- NCT03585127
- Testing
- Cognitive Behavioral Therapy, Avatar Therapy
- Where
- Canada
- Volunteers
- 74 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Schizophrenia, Schizo Affective Disorder
Telmisartan Pilot Study on Treatment Resistant Schizophrenia
This study is a 4-week pilot study for subjects with Schizophrenia or Schizoaffective Disorder who have not experienced a significant relief of symptoms from current anti-psychotic medication.
- Conditions
- Schizophrenia, Schizo Affective Disorder, Treatment-resistant Schizophrenia
- Trial name
- NCT03868839
- Testing
- Telmisartan Pill
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Xiaoduo Fan
Schizophrenia
DAAOI-2 add-on Treatment for Treatment-resistant Schizophrenia
Pharmacotherapy for schizophrenia has limitations such as residual positive and negative symptoms, cognitive deficits and intolerable side effects. Refractory schizophrenia is still a difficult clinical issue at present.
- Trial name
- NCT02532686
- Testing
- DAAOI-2
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- China Medical University Hospital
Difference in the Change in Cardiovascular Risk in Treatment Resistant Schizophrenia
Add-on Aripiprazole on Cardiometabolic Profile in Treatment Resistant Schizophrenia: RCT
The goal of this clinical trial participant population is to evaluate the effect of add on Aripiprazole in reducing the metabolic parameters in patients of TRS on Clozapine with metabolic syndrome.
- Trial name
- NCT05766540
- Testing
- Aripiprazole 10 MG
- Volunteers
- 60 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Schizophrenia, Schizoaffective Disorder
Olanzapine Versus Clozapine in Treatment Refractory Schizophrenia
The study involves a six-month, double-blind protocol during which eighty patients, across three sites around the country, will be randomly assigned to receive clozapine or olanzapine.
- Trial name
- NCT00179231
- Testing
- olanzapine vs. clozapine
- Volunteers
- 80 people
- Sponsor
- Vanderbilt University
Schizophrenia
The Optimal Treatment for Treatment-resistant Schizophrenia
The Optimal Treatment for Treatment-resistant Schizophrenia
- Trial name
- NCT02926976
- Testing
- Risperidone with Clozapine, Aripiprazole with Clozapine, sodium valproate with Clozapine
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia; Negative Type
Deep Brain Stimulation (DBS) for the Management of Treatment Refractory Negative Symptoms in Schizophrenia
Schizophrenia is a complex, challenging, and heterogeneous psychiatric condition, affecting up to 0.5% of the population and responsible for nearly 2% of all Canadian health-care expenditure.
- Trial name
- NCT01725334
- Testing
- Deep Brain Stimulation
- Where
- Canada
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia
High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia
The aim of this study is to compare the efficacy of a flexible high dose of lurasidone to a standard dose of lurasidone in patients with treatment resistant schizophrenia or schizoaffective disorder.
- Trial name
- HDL (NCT01569659)
- Testing
- Lurasidone
- Where
- 2 sites in United States
- Volunteers
- 101 people
- Sponsor
- Northwestern University
Treatment-resistant Schizophrenia
Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients
This study includes two main components: the first screening phase and the second clinical intervention phase. During the screening phase, subjects with poor response to clozapine are carefully evaluated by chart-review and…
- Trial name
- M1106 (NCT01105481)
- Testing
- Amisulpride add-on
- Where
- 2 sites in Taiwan
- Volunteers
- 273 people
- Sponsor
- National Health Research Institutes, Taiwan
Schizophrenia, Treatment-resistant Schizophrenia
Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis
SchizOMICS is a Phase IV, multicenter, dose-flexible, open-label, randomized controlled clinical trial to evaluate the efficacy and safety of aripiprazole versus paliperidone using multi-omics data in patients with a first…
- Conditions
- Schizophrenia, Treatment-resistant Schizophrenia, Side Effect, Lipid Metabolism Disorders
- Trial name
- SchizOMICS (NCT06060886)
- Testing
- Aripiprazole, Paliperidone
- Volunteers
- 244 people
- Sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
Treatment-Refractory Schizophrenia
Deep Brain Stimulation for Psychosis
There are three hypotheses proposed for this study: 1) Participants will report no unanticipated serious adverse events during the eight months of treatment.
- Trial name
- NCT06257056
- Testing
- Abbott Laboratories Infinity™ implantable deep brain stimulation system
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Bradley Lega
Schizophrenia, Treatment Resistant Schizophrenia
Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial
Schizophrenia is one of the most severe and costliest mental disorders in terms of human suffering and societal expenditure. About 15-30% of patients do not respond to all known antipsychotics, including clozapine, the current…
- Trial name
- MECT-RESIST (NCT06456983)
- Testing
- maintenance electroconvulsive therapy (mECT)
- Where
- 14 sites in Germany
- Volunteers
- 140 people
- Sponsor
- Central Institute of Mental Health, Mannheim
Schizophrenia, Auditory Hallucination
Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations
Neurofeedback intervention aimed to regulate the superior temporal gyrus (STG) activation and default mode network (DMN) connectivity as well as to reduce the auditory hallucinations (AH) schizophrenia patients with medication…
- Conditions
- Schizophrenia, Auditory Hallucination, Treatment-resistant Schizophrenia
- Trial name
- NCT05299749
- Testing
- stg-rt-fMRI-Neurofeeback
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Boston VA Research Institute, Inc.
Schizophrenia, Treatment Refractory
GlyT-1 Inhibitor Treatment for Refractory Schizophrenia
The etiology of schizophrenia remains unclear In recent one decade, hypofunction of N-methyl-D-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia.
- Trial name
- NCT01251055
- Testing
- GlyT-1 inhibitor-1
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- China Medical University Hospital
Schizophrenia
Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia
The purpose of this study is to determine whether aripiprazole augmentation is safe and effective in the treatment of clozapine-treated patients with refractory schizophrenia.
- Trial name
- NCT00328367
- Testing
- aripiprazole
- Where
- South Korea
- Volunteers
- 61 people
- Sponsor
- Seoul National University Hospital
Schizophrenia
D-serine in Schizophrenia
This study will assess the effects of D-serine adjuvant treatment to the ongoing pharmacological treatment of schizophrenia patients that are resistant to treatments.
- Trial name
- DSRSZ (NCT03702933)
- Testing
- D-serine
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Herzog Hospital
Schizophrenia, Auditory Hallucinations
A Pilot Double-blind Sham-controlled Trial of Repetitive Transcranial Magnetic Stimulation for Patients With Refractory Schizophrenia Treated With Clozapine
The primary outcome of this study is to evaluate the effects of low frequency subthreshold repetitive Transcranial Magnetic Stimulation applied to the left temporoparietal cortex of patients with refractory schizophrenia on the…
- Trial name
- NCT01015001
- Testing
- (1Hz) rTMS applied over the left temporoparietal cortex
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Hospital de Clinicas de Porto Alegre